CV Sciences Inc (CVSI)
OTHER OTC:CVSI
Want to see CVSI full AI Analyst Report?
CVSI Stock Chart & Stats
$0.09
>-$0.01(-7.69%)
At close: 4:00 PM EST
$0.09
>-$0.01(-7.69%)
Day’s Range― - ―
52-Week Range$0.02 - $0.10
Previous CloseN/A
Volume110.38K
Average Volume (3M)246.65K
Market Cap
$5.83M
Enterprise Value$7.02M
Total Cash (Recent Filing)$278.00K
Total Debt (Recent Filing)$1.61M
Price to Earnings (P/E)―
Beta0.57
Next Earnings
Aug 17, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding193,458,420
10 Day Avg. Volume158,629
30 Day Avg. Volume246,649
Financial Highlights & Ratios
PEG Ratio0.19
Price to Book (P/B)7.71
Price to Sales (P/S)0.82
P/FCF Ratio-21.93
Enterprise Value/Market Cap1.20
Enterprise Value/Revenue0.51
Enterprise Value/Gross Profit1.04
Enterprise Value/Ebitda-12.49
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Margin & Profitability ImprovementSustained gross margin uplift and material operating expense cuts reduce the company's break-even and improve operational leverage. Positive adjusted EBITDA in Q4 signals the business model can generate operating cash at scale if revenue stabilizes, supporting longer-term profitability prospects.
Balance-sheet RestructuringReplacing monthly cash redemptions with amended convertible notes materially reduces near-term cash outflows, easing liquidity pressure. The structure gives management flexibility to manage obligations and prioritize operational recovery, improving runway and strategic optionality over months.
Product Innovation & DiversificationA high share of recent revenue from post-2023 launches shows the company can develop and commercialize new SKUs. Continued product cadence and category expansion (non-CBD lines noted) diversify revenue streams and reduce reliance on legacy SKUs, supporting medium-term growth resilience.
Bears Say
Revenue Decline & VolatilityFalling top-line reduces scale benefits and strains gross profit conversion into cash. Revenue volatility undermines planning and makes fixed-cost absorption harder, meaning margin gains may not translate to sustained profitability unless revenue stabilizes or grows consistently over the next several quarters.
Weak Cash GenerationReversion to negative operating and free cash flow increases dependence on external financing. Persistent cash burn limits reinvestment in marketing and product development, elevates liquidity risk, and can force dilutive financing or asset sales if operational cash generation does not recover.
Rising Leverage & Dilution RiskHigher leverage reduces financial flexibility and the new convertible structure creates substantial dilution risk if converted. True-up provisions and potential for additional senior notes mean capital needs could translate into equity issuance, weakening shareholder claims and increasing funding uncertainty.
CV Sciences News
CVSI FAQ
What was CV Sciences Inc’s price range in the past 12 months?
CV Sciences Inc lowest stock price was $0.02 and its highest was $0.10 in the past 12 months.
What is CV Sciences Inc’s market cap?
CV Sciences Inc’s market cap is $5.83M.
When is CV Sciences Inc’s upcoming earnings report date?
CV Sciences Inc’s upcoming earnings report date is Aug 17, 2026 which is in 100 days.
How were CV Sciences Inc’s earnings last quarter?
Currently, no data Available
Is CV Sciences Inc overvalued?
According to Wall Street analysts CV Sciences Inc’s price is currently Overvalued.
Does CV Sciences Inc pay dividends?
CV Sciences Inc does not currently pay dividends.
What is CV Sciences Inc’s EPS estimate?
CV Sciences Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does CV Sciences Inc have?
CV Sciences Inc has 193,458,420 shares outstanding.
What happened to CV Sciences Inc’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of CV Sciences Inc?
Currently, no hedge funds are holding shares in CVSI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
CV Sciences Inc
CV Sciences, Inc. (CVSI) is a biotechnology company focused on the research, development, and commercialization of products derived from hemp extract, particularly those containing cannabidiol (CBD). Operating primarily in the wellness and pharmaceutical sectors, CV Sciences offers a range of products including dietary supplements, topical applications, and pharmaceutical formulations aimed at promoting health and well-being. The company is dedicated to providing high-quality, science-backed products that leverage the therapeutic potential of cannabinoids.
CVSI Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted significant improvements in gross margin, cash flow, and cost efficiency, alongside successful new product developments and strategic M&A integration. However, challenges such as revenue decline, regulatory issues, and a decrease in B2C revenue were noted. Despite these challenges, the company's positive adjusted EBITDA and improved financial metrics demonstrate progress towards profitability.View all CVSI earnings summariesTechnical Analysis
cbdMD
―
Cosmos Holdings
―
IM Cannabis Corp
―
―
Incannex Healthcare Limited Sponsored ADR
―
Ownership Overview
―
Insiders
―
Mutual Funds
<0.01% Other Institutional Investors
100.00% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---